Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events.
He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been plagued with a myriad of troubling data suggesting that the technology is linked to thrombosis and target lesion failure.
Newly-developed scaffolds are only just beginning to live up to thin-strut metallic drug-eluting stents, Colombo told the audience at this year’s EuroPCR meeting.
“It’s a little bit sad that we went through mega-trials with devices that are so 1st generation when we almost have in our pocket a new-generation device,” the co-principal investigator said.
Get the full story at our sister site, Drug Delivery Business News.
The post Amaranth Medical looks to recapture the potential of bioresorbable scaffolds appeared first on MassDevice.